<DOC>
	<DOCNO>NCT02522377</DOCNO>
	<brief_summary>In proof concept study , investigator plan administer iv ketamine interleave ECT day . Patients treatment resistant depression deem eligible ECT treatment randomly assign either ketamine active placebo .</brief_summary>
	<brief_title>Administration Subanesthetic Dose Ketamine Electroconvulsive Treatment Treatment Resistant Depression</brief_title>
	<detailed_description>The study compare effect standard ketamine dose active placebo arm . Hypothesis 1 : The investigator hypothesize interleaved Electroconvulsive Treatment active ketamine treatment lead meaningful clinical improvement compare Electroconvulsive Treatment placebo treatment arm . Hypothesis 2 : The investigator hypothesize interleaved Electroconvulsive Treatment active ketamine treatment attenuate cognitive side effect . Methods Design : Patients treatment resistant depression deem eligible Electroconvulsive Treatment randomly assign either ketamine active placebo Electroconvulsive Treatments : All patient ( independent depression score ) receive Electroconvulsive Treatment parameter : Bi-frontal brief pulse ( 0.5 miliseconds ) Electroconvulsive Treatment administer use Thymatron Electroconvulsive Treatment machine . Study blinding : Neither patient , treat psychiatrist nurse aware patient 's assigned arm . The success blinding test ketamine treatment questionnaire give subject , raters , treat physician .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Males/females least 18 year age old 65 year age 2 . Meet Diagnostic Statistical Manual Mental Disorders4th Edition ( DSMIV ) criteria Major Depression Bipolar Disorder , depress phase , determine clinician 's diagnostic evaluation confirm interview use Mini International Neuropsychiatric Interview ( MINI PLUS 5.0.0 ) 3 . A current depressive episode last minimum 4 week . 4 . Have &gt; 3 trial antidepressants/augmentation strategy . 5 . Have support system capable transport patient posttreatment . 1 . Meeting Diagnostic Statistical Manual Mental Disorders criterion schizophrenia , schizophreniform disorder , schizoaffective disorder , mental retardation , pervasive developmental disorder . 2 . Meeting Diagnostic Statistical Manual Mental Disorders criterion substance/alcohol dependence within past 6 month abuse past 3 month . 3 . Patients meet exclusion criterion ketamine and/or midazolam infusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>Electroconvulsive Therapy</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Treatment Resistant Depression</keyword>
	<keyword>electroconvulsive treatment</keyword>
	<keyword>Severe depression</keyword>
</DOC>